{"id":221,"date":"2023-04-04T15:26:00","date_gmt":"2023-04-04T15:26:00","guid":{"rendered":"https:\/\/www.veratech.es\/?p=221"},"modified":"2024-01-02T14:04:38","modified_gmt":"2024-01-02T14:04:38","slug":"2-knowledge_center-prueba-2","status":"publish","type":"post","link":"http:\/\/veratech.es\/en\/2023\/04\/04\/2-knowledge_center-prueba-2\/","title":{"rendered":"Contextualizing adverse events of special interest to characterize baseline incidence rates in 24 million COVID-19 patients across 26 databases: a multinational retrospective cohort study."},"content":{"rendered":"<p>A multinational cohort study analysed the incidence of adverse events of special interest (AESI) following COVID-19 infection and compared them with historical rates in the general population. Primary care, electronic health records and insurance claims data were collected from multiple databases between January 2017 and May 2022. Sixteen pre-specified AESIs were identified, including acute myocardial infarction, anaphylaxis, stroke, thrombosis and myocarditis, among others.<\/p>","protected":false},"excerpt":{"rendered":"<p>Un estudio de cohortes multinacional analiz\u00f3 la incidencia de acontecimientos adversos de especial inter\u00e9s (AESI) despu\u00e9s de la infecci\u00f3n por COVID-19 y los compar\u00f3 con las tasas hist\u00f3ricas en la poblaci\u00f3n general. Se recopilaron datos de atenci\u00f3n primaria, registros sanitarios electr\u00f3nicos y reclamaciones de seguros de m\u00faltiples bases de datos entre enero de 2017 y mayo de 2022. Se identificaron 16 AESI preespecificados, como infarto agudo de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[17,14],"class_list":["post-221","post","type-post","status-publish","format-standard","hentry","category-knowledge_center","tag-https-www-thelancet-com-journals-eclinm-article-piis2589-53702300109-8-fulltext","tag-reuso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional. - Veratech for Health<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/veratech.es\/en\/2023\/04\/04\/2-knowledge_center-prueba-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional. - Veratech for Health\" \/>\n<meta property=\"og:description\" content=\"Un estudio de cohortes multinacional analiz\u00f3 la incidencia de acontecimientos adversos de especial inter\u00e9s (AESI) despu\u00e9s de la infecci\u00f3n por COVID-19 y los compar\u00f3 con las tasas hist\u00f3ricas en la poblaci\u00f3n general. Se recopilaron datos de atenci\u00f3n primaria, registros sanitarios electr\u00f3nicos y reclamaciones de seguros de m\u00faltiples bases de datos entre enero de 2017 y mayo de 2022. Se identificaron 16 AESI preespecificados, como infarto agudo de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/veratech.es\/en\/2023\/04\/04\/2-knowledge_center-prueba-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Veratech for Health\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T15:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-02T14:04:38+00:00\" \/>\n<meta name=\"author\" content=\"veraweb23update\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@veratech\" \/>\n<meta name=\"twitter:site\" content=\"@veratech\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"veraweb23update\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/\"},\"author\":{\"name\":\"veraweb23update\",\"@id\":\"https:\\\/\\\/veratech.es\\\/#\\\/schema\\\/person\\\/205ab530575337ab02ada32882b4087c\"},\"headline\":\"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional.\",\"datePublished\":\"2023-04-04T15:26:00+00:00\",\"dateModified\":\"2024-01-02T14:04:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/\"},\"wordCount\":116,\"publisher\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/#organization\"},\"keywords\":[\"https:\\\/\\\/www.thelancet.com\\\/journals\\\/eclinm\\\/article\\\/PIIS2589-5370(23)00109-8\\\/fulltext\",\"Reuso\"],\"articleSection\":[\"Knowledge_center\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/\",\"url\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/\",\"name\":\"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional. - Veratech for Health\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/#website\"},\"datePublished\":\"2023-04-04T15:26:00+00:00\",\"dateModified\":\"2024-01-02T14:04:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/veratech.es\\\/2023\\\/04\\\/04\\\/2-knowledge_center-prueba-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/veratech.es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/veratech.es\\\/#website\",\"url\":\"https:\\\/\\\/veratech.es\\\/\",\"name\":\"Veratech for Health\",\"description\":\"Somos una consultor\u00eda de interoperabilidad sem\u00e1ntica que te ayuda a gestionar tus datos\",\"publisher\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/veratech.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/veratech.es\\\/#organization\",\"name\":\"Veratech for Health\",\"url\":\"https:\\\/\\\/veratech.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/veratech.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/veratech.es\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/VT_15Aniversario.png\",\"contentUrl\":\"https:\\\/\\\/veratech.es\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/VT_15Aniversario.png\",\"width\":1920,\"height\":538,\"caption\":\"Veratech for Health\"},\"image\":{\"@id\":\"https:\\\/\\\/veratech.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/veratech\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/2261467\\\/admin\\\/dashboard\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/veratech.es\\\/#\\\/schema\\\/person\\\/205ab530575337ab02ada32882b4087c\",\"name\":\"veraweb23update\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68854fecc296ff46e6e2697dbc6f148ffba060959fd4c460dd6e5005601b2e09?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68854fecc296ff46e6e2697dbc6f148ffba060959fd4c460dd6e5005601b2e09?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68854fecc296ff46e6e2697dbc6f148ffba060959fd4c460dd6e5005601b2e09?s=96&d=mm&r=g\",\"caption\":\"veraweb23update\"},\"sameAs\":[\"http:\\\/\\\/localhost\\\/veratech-web\"],\"url\":\"http:\\\/\\\/veratech.es\\\/en\\\/author\\\/veraweb23update\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional. - Veratech for Health","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/veratech.es\/en\/2023\/04\/04\/2-knowledge_center-prueba-2\/","og_locale":"en_GB","og_type":"article","og_title":"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional. - Veratech for Health","og_description":"Un estudio de cohortes multinacional analiz\u00f3 la incidencia de acontecimientos adversos de especial inter\u00e9s (AESI) despu\u00e9s de la infecci\u00f3n por COVID-19 y los compar\u00f3 con las tasas hist\u00f3ricas en la poblaci\u00f3n general. Se recopilaron datos de atenci\u00f3n primaria, registros sanitarios electr\u00f3nicos y reclamaciones de seguros de m\u00faltiples bases de datos entre enero de 2017 y mayo de 2022. Se identificaron 16 AESI preespecificados, como infarto agudo de [&hellip;]","og_url":"https:\/\/veratech.es\/en\/2023\/04\/04\/2-knowledge_center-prueba-2\/","og_site_name":"Veratech for Health","article_published_time":"2023-04-04T15:26:00+00:00","article_modified_time":"2024-01-02T14:04:38+00:00","author":"veraweb23update","twitter_card":"summary_large_image","twitter_creator":"@veratech","twitter_site":"@veratech","twitter_misc":{"Written by":"veraweb23update","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/#article","isPartOf":{"@id":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/"},"author":{"name":"veraweb23update","@id":"https:\/\/veratech.es\/#\/schema\/person\/205ab530575337ab02ada32882b4087c"},"headline":"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional.","datePublished":"2023-04-04T15:26:00+00:00","dateModified":"2024-01-02T14:04:38+00:00","mainEntityOfPage":{"@id":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/"},"wordCount":116,"publisher":{"@id":"https:\/\/veratech.es\/#organization"},"keywords":["https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(23)00109-8\/fulltext","Reuso"],"articleSection":["Knowledge_center"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/","url":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/","name":"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional. - Veratech for Health","isPartOf":{"@id":"https:\/\/veratech.es\/#website"},"datePublished":"2023-04-04T15:26:00+00:00","dateModified":"2024-01-02T14:04:38+00:00","breadcrumb":{"@id":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/veratech.es\/2023\/04\/04\/2-knowledge_center-prueba-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/veratech.es\/"},{"@type":"ListItem","position":2,"name":"Contextualizaci\u00f3n de los acontecimientos adversos de especial inter\u00e9s para caracterizar las tasas de incidencia basales en 24 millones de pacientes con COVID-19 a trav\u00e9s de 26 bases de datos: un estudio de cohortes retrospectivo multinacional."}]},{"@type":"WebSite","@id":"https:\/\/veratech.es\/#website","url":"https:\/\/veratech.es\/","name":"Veratech for Health","description":"Somos una consultor\u00eda de interoperabilidad sem\u00e1ntica que te ayuda a gestionar tus datos","publisher":{"@id":"https:\/\/veratech.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/veratech.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/veratech.es\/#organization","name":"Veratech for Health","url":"https:\/\/veratech.es\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/veratech.es\/#\/schema\/logo\/image\/","url":"https:\/\/veratech.es\/wp-content\/uploads\/2025\/03\/VT_15Aniversario.png","contentUrl":"https:\/\/veratech.es\/wp-content\/uploads\/2025\/03\/VT_15Aniversario.png","width":1920,"height":538,"caption":"Veratech for Health"},"image":{"@id":"https:\/\/veratech.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/veratech","https:\/\/www.linkedin.com\/company\/2261467\/admin\/dashboard\/"]},{"@type":"Person","@id":"https:\/\/veratech.es\/#\/schema\/person\/205ab530575337ab02ada32882b4087c","name":"veraweb23update","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/68854fecc296ff46e6e2697dbc6f148ffba060959fd4c460dd6e5005601b2e09?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/68854fecc296ff46e6e2697dbc6f148ffba060959fd4c460dd6e5005601b2e09?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68854fecc296ff46e6e2697dbc6f148ffba060959fd4c460dd6e5005601b2e09?s=96&d=mm&r=g","caption":"veraweb23update"},"sameAs":["http:\/\/localhost\/veratech-web"],"url":"http:\/\/veratech.es\/en\/author\/veraweb23update\/"}]}},"_links":{"self":[{"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/posts\/221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/comments?post=221"}],"version-history":[{"count":2,"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/posts\/221\/revisions"}],"predecessor-version":[{"id":228,"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/posts\/221\/revisions\/228"}],"wp:attachment":[{"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/media?parent=221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/categories?post=221"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/veratech.es\/en\/wp-json\/wp\/v2\/tags?post=221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}